You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.
The company's HIV testing revenues were up 24 percent year over year, while HCV testing revenues plummeted 68 percent.
LabCorp Diagnostics revenues increased 9 percent in Q4, while Covance Drug Development grew revenues 24 percent.
Savings from the recently passed tax legislation are expected to more than offset headwinds from PAMA legislation, executives said.
Within the centralized and point-of-care solutions business, integrated serum work area solutions drove growth with immunodiagnostics sales rising 13 percent.
Qiagen posted revenues of $396.9 million in Q4 compared to $366.5 million a year ago and beat analysts' estimates on both the top and bottom lines.
The company's full year revenues increased 14 percent over 2016, to $20.92 billion.
Revenues in PerkinElmer's diagnostics business rose 23 percent in Q4, thanks largely to its acquisition of autoimmune diagnostic testing firm Euroimmun.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.
Among the diagnostic firms presenting at the conference on Tuesday were lab giant LabCorp, diversified medical products firm Hologic, and MDx startups, such as Adaptive Biotechnologies.